TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Rehabilitation Team Functioning and Patient Outcomes
Brief Summary: The purpose of the study is to determine if 1. Rehabilitation staff can be trained to work better together as a team; and 2. Better team work improves patient outcomes.


Options:
A: Inclusion Criteria:

* Principal diagnosis of Ischemic Stroke (ICD9CM code 434.91)

Exclusion Criteria:

* Transient cerebral ischemia (ICD9CM code 435.9)
* Intracerebral hemorrhage (ICD9CM codes 431.xx)
B: Inclusion Criteria:

* Randomized, controlled subjects were VA inpatient rehabilitation teams. Secondary data included telephone surveys from discharged patients treated by the rehabilitation teams.

Exclusion Criteria:

* VA sites which did not submit data to the VA-FSOD - the national functional outcomes database
C: Inclusion Criteria:

* English and Spanish speaking stroke patients with diagnosis of ischemic stroke, hemorrhagic stroke or TIA who are discharged home from participating hospitals
* Must be 18 years of age and older at the time of the stroke

Exclusion Criteria:

* Excludes subdural or aneurysmal subarachnoid hemorrhage
D: Inclusion criteria:

* Older than 18
* Ischemic stroke within 7 days of the index event
* Direct admission based on physician evaluation or arrival through the emergency department
* Ability of patient or legally authorized representative to provide informed consent for 3, 6,and 12 months after initial symptom onset
* Eligible events were confirmed by brain ct or mri within7 days after the onset of symptoms

Exclusion criteria:

* Patients refuse to participate in this study

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Rehabilitation Team Functioning and Patient Outcomes
Brief Summary: The purpose of the study is to determine if 1. Rehabilitation staff can be trained to work better together as a team; and 2. Better team work improves patient outcomes.


Options:
A: Inclusion Criteria:

Home-dwelling patients aged 65 or higher, who have a diagnosis of depression, according to International Statistical Classification of Diseases and Related Health Problems, Tenth Revision

Exclusion Criteria:

Patients will be excluded if they have a diagnosis of dementia, bipolar disorder or reside in nursing homes or is assessed by their practitioner to have low life expectancy.
B: Inclusion Criteria:

* Randomized, controlled subjects were VA inpatient rehabilitation teams. Secondary data included telephone surveys from discharged patients treated by the rehabilitation teams.

Exclusion Criteria:

* VA sites which did not submit data to the VA-FSOD - the national functional outcomes database
C: Inclusion Criteria:

* 18 years of age and older
* at least 20 intact natural teeth, excluding third molars
* 2 or more lesions, of which at least one must be a cavitated D2 or D3
* willing and able to provide informed consent

Exclusion Criteria

* pregnant or planning to become pregnant or planning to become pregnant during the study (breastfeeding is permitted)
* use of fixed orthodontic appliances
* allergic to any of the ingredients of the study medication
* long-term antibiotic therapy
* a history of, or currently active, radiation therapy for cancers of the head or neck
* Sjögren's syndrome
* advanced periodontitis
* consumption of the equivalent of more than five servings of acidic or sugared drinks per day
* having 10 or more lesions requiring restorative care at the time of the screening visit
* remineralization therapy within one month of randomization
* investigator discretion
D: Health Facility Inclusion criteria:

* Located in lowland Muheza, adjoining wards of Handeni, or any area of Moshi Rural Districts
* Health facilities that are registered with the District Health Authority
* Receives Government supplies of ALu and qualifies for RDT supply
* Agrees to exclusive use of RDT for routine diagnosis of first consultations for possible malaria
* Accessible by 4-wd vehicle throughout the year.
* Availability of data on proportion of consultations diagnosed with malaria in 2008 (or earliest available year)

Health Facility Exclusion:

* Presence of other research in the immediate area where study procedures could bias outcomes in either study.
* Fewer than 500 cases per year were reported in 2005 or 2006.

Patient Inclusion:

* All patients with non-severe illness in first consultations.
* Patient Exclusion
* Patients who have been referred to the next level of care
* Patient refuses consent to exit survey
* Follow-up consultations

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Comparison of Symbicort® Single Inhaler Therapy (Symbicort® 200 Turbuhaler® 1 Inhalation b.i.d. Plus as Needed) & Conventional Best Practice for the Treatment of Persistent Asthma in Adolescents & Adults-a 26-Week, Randomised, Open-Label, Parallel Group, Multicentre Study
Brief Summary: The purpose of this study is to compare Symbicort Single Inhaler treatment with the Best Conventional Practice in patients with persistent asthma


Options:
A: Inclusion Criteria:

* Diagnosed with asthma since at least 6 months prior to first visit
* Prescribed daily use of glucocorticosteroids for at least 3 months prior to first visit
* At least one asthma exacerbation more than one but less than twelve months prior to first visit

Exclusion Criteria:

* Respiratory infection affecting asthma within 30 days before first visit
* Use of oral, rectal, or parenteral glucocorticosteroids for within 30 days before first visit
* Any significant disease or disorder that may jeopardize the safety of the patient

Additional inclusion and exclusion criteria will be evaluated by the Investigator.
B: Inclusion Criteria:

* diagnosis of mild to moderate asthma, FEV1 ³ 60% of predicted normal values pre-bronchodilator, daily use of inhaled GCS during the last 3 months

Exclusion Criteria:

* Regular need of \>4 inhalations of a short-acting b2-agonist/day, known or suspected hypersensitivity to any of the investigational drugs or inhaled lactose, use of any b-blocking agent, having smoked ³10 pack-years
C: Inclusion Criteria:

* Patients at out-patient clinics
* \>18 years with a minimum of 6 months documented history of persistent asthma who have used inhaled glucocorticosteroids for at least one month and have a history of use in rapid-acting B2 agonists for symptom relief

Exclusion Criteria:

* Asthma exacerbation within the last 14 days prior to study start
* subject aged \>40 years with a smoking history of \>10pack-years
* subjects with chronic obstructive lung disease or other significant respiratory disease
D: Inclusion Criteria:

* Diagnosis of asthma \< 3 months
* Prescribed daily use of glucocorticosteroids for at least 3 months prior to Visit 1

Exclusion Criteria:

* Smoking history \> 10 pack-years
* Asthma exacerbation requiring change in asthma treatment during the last 14 days prior to inclusion
* Any significant disease or disorder that my jeopardize the safety of the patient.

Additional inclusion and exclusion criteria will be evaluated by the investigator.

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: N/A
Brief Summary: The University of Ottawa and Élisabeth Bruyère Research Institute are conducting a study of preventive care for frail patients at risk of functional decline. At risk patients are assigned by chance to continue receiving their standard care from their family physician or receive additional care from a nurse practitioners and a pharmacist. In collaboration with the family physician, they develop an individualized care plan, a treatment and management road plan, for each patient, which they implement over the study period of one approximately year. The objective of the study is to compare the effectiveness of the model of care that includes the nurse practitioners and pharmacist against standard care in preventing functional decline, to determine the acceptability of this model of care to patients, their caregivers and the medical team, and to evaluate the cost implication of the program.


Options:
A: Inclusion Criteria:

* medical patients discharged to home or skilled nursing facility between October 1, 2011 and June 30, 2013
* Cambridge Health Alliance PCP at time of discharge
* at least one of four risk factors for readmission: discharge diagnosis of CHF or COPD; length of stay \>3 days; age \>60; or previous hospitalization within the past 6 months
B: Inclusion Criteria:

* Diabetes mellitus
* Elevated depressive symptoms (regarding to CES-D)
* Age \>= 18 and \<=70
* Sufficient German language skills
* Informed consent

Exclusion Criteria:

* Current MDD
* Current schizophrenia/ psychotic disorder, eating disorder, bipolar disorder, addictive disorder, personality disorder
* Current antidepressive medication
* Current psychotherapy
* Severe physical illness (i.e. cancer)
* Being bedridden
* Guardianship
C: Inclusion Criteria:

* patients aged 65 years and older
* must have a minimum of three chronic or vitality threatening diseases and/or use five or more medical drugs chronically in the last year
* must have dyspnea and/or reduced exercise tolerance (scored by two short questionnaires)

Exclusion Criteria:

* patients with both confirmed COPD and heart failure (Spirometry performed \< 1 year ago and heart failure confirmed by echocardiography)
* patients unable or unwilling to sign informed consent
D: Inclusion Criteria:

* 50 years and over
* 'At Risk' by having one or more of the following: a. Visits to emergency dept within the past 6 months; b. Admission to hospital for a medical problem in past 6 months; c. High service use profiles; d. Polypharmacy; e. Other high risk factors
* Capable of giving informed consent
* Able to use the Care Companion technology

Exclusion Criteria:

* Cognitive impairment such that they cannot give informed consent
* Unable or unwilling to use the telehomecare equipment
* Unlikely to tolerate the intensive intervention
* Language or cultural barriers
* Being acutely ill or having an unstable condition on entry to the study

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: N/A
Brief Summary: The University of Ottawa and Élisabeth Bruyère Research Institute are conducting a study of preventive care for frail patients at risk of functional decline. At risk patients are assigned by chance to continue receiving their standard care from their family physician or receive additional care from a nurse practitioners and a pharmacist. In collaboration with the family physician, they develop an individualized care plan, a treatment and management road plan, for each patient, which they implement over the study period of one approximately year. The objective of the study is to compare the effectiveness of the model of care that includes the nurse practitioners and pharmacist against standard care in preventing functional decline, to determine the acceptability of this model of care to patients, their caregivers and the medical team, and to evaluate the cost implication of the program.


Options:
A: Inclusion Criteria:

* people aged 75 years or older

Exclusion Criteria:

* people aged 75 years or older
* refusal of consent to participate
* a life expectancy of less than 6 months
B: Inclusion Criteria:

* 50 years and over
* 'At Risk' by having one or more of the following: a. Visits to emergency dept within the past 6 months; b. Admission to hospital for a medical problem in past 6 months; c. High service use profiles; d. Polypharmacy; e. Other high risk factors
* Capable of giving informed consent
* Able to use the Care Companion technology

Exclusion Criteria:

* Cognitive impairment such that they cannot give informed consent
* Unable or unwilling to use the telehomecare equipment
* Unlikely to tolerate the intensive intervention
* Language or cultural barriers
* Being acutely ill or having an unstable condition on entry to the study
C: Inclusion Criteria:

* 70+ years
* must be living at home
* screening positive (DEMTECT \< 9), indicating dementia

Exclusion Criteria:

* medical conditions not allowing testing
D: Inclusion Criteria:

* 70 years or more
* Currently receiving eight or more drugs, except ointments and administered via topical nonprescription
* Give their informed written consent to participate in the study.

Exclusion Criteria:

* Estimated life expectancy less than 6 months.
* Active cancer
* Participation in any other clinical trial or program for evaluation of medication in the elderly.
* Institutionalized in nursing homes.
* Surgical intervention scheduled for the next 6 months

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Effects of High Dose Inhaled Budesonide+ Formoterol Versus Placebo and Oral Prednisolone on Biomarkers of Airway Inflammation in the Treatment of Exacerbations in Non-hospitalised Patients With Mild to Moderate COPD.
Brief Summary: The purpose of this study is to determine whether the budesonide+formoterol combination is effective in the treatment of exacerbations of COPD with a main emphasis on investigating the effects on inflammation and a secondary emphasis on clinical efficacy


Options:
A: Inclusion Criteria:

* A clinical diagnosis of COPD with symptoms for more than 2 years.
* Smoking history of 10 or more pack years
* A history of at least one COPD exacerbation requiring a course of oral steroids and/or antibiotics within 1-12 months before first visit.

Exclusion Criteria:

* A history of asthma
* Patients taking oral steroids
* Any significant disease or disorder that may jeopardize the safety of the patient
B: Inclusion Criteria:

* A clinical diagnosis of COPD with symptoms for more than 2 years
* Smoking history of 10 or more pack years
* A history of at least one COPD exacerbation requiring a course of oral steroids and/or antibiotics within 1-12 months before first visit.

Exclusion Criteria:

* A history of asthma
* Patients taking oral steroids.
* Any significant disease or disorder that may jeopardize the safety of the patient
C: Inclusion Criteria:

* All patients must have a clinical diagnosis of chronic obstructive pulmonary disease according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines.
* Patients must have a cigarette smoking history of more than 10 pack-years
* Patients must be clinically stable and at least 4 weeks from last acute exacerbation (and return to baseline level of symptoms)
* Patients must have an FEV1 of less than 80% of predicted values with FEV1 to FVC ratio of less than 0.70 (post-bronchodilator values)
* Men or women ≥ 45 years of age
D: Inclusion Criteria:

* smoking-induced COPD according to ATS criteria
* FEV1 \<85% of predicted at enrolment and \<70% of predicted but \> 0.7 Liter at Exacerbation
* FEV1/IVC ratio \<88% of predicted for men and \<89% for women

Exclusion Criteria:

* history of asthma
* known hypersensitivity to the study drugs
* serious concomitant diseases
* pregnancy or lactating
* abnormal Chest X-ray or blood gasses

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Randomised, Double-Blind, Double-Dummy, Placebo- and Active-Controlled, Parallel Group Efficacy and Safety Comparison of 12-Week Treatment of Two Doses [5 μg (2 Actuations of 2.5 μg) and 10 μg (2 Actuations of 5 μg)] of Tiotropium Inhalation Solution Delivered by the Respimat Inhaler, Placebo and Ipratropium Bromide Inhalation Aerosol (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: The primary objective was to compare the bronchodilator efficacy of two doses (5 mcg and 10 mcg) of tiotropium inhalation solution delivered by the Respimat inhaler once daily to placebo and to ipratropium bromide MDI four times daily in patients with COPD. The secondary objective was to compare the safety of tiotropium inhalation solution delivered by the Respimat to placebo and ipratropium bromide MDI.


Options:
A: Diagnosis of COPD and matching the following criteria:

* Baseline 20 % \< FEV1 \< 70 % of European Community of Coal and Steel (ECCS) predicted values .
* Baseline FEV1/SVC\< 70 %. Smoking history \> 10 pack-years (p.y.). A p.y. was defined as the equivalent of smoking one pack of cigarettes per day for one year.
B: Outpatients of either sex, aged \>/= 40 years with a diagnosis of COPD (FEV1 \</= 60% predicted \[ECCS criteria\] and FEV1/FVC \</= 70%)
C: N/A
D: Inclusion Criteria:

* History of COPD, FEV1 less than or equal to 65%, FEV1/FVC less than or equal 70%
* Smoking history greater than or equal to 10 pack years
* Not history of clinical diagnosis of asthma and/or atopy
* A history of thoracotomy with pulmonary resection
* Patients requiring the use of supplemental oxygen therapy for \>12 hours per day
* Chronic use of systemic corticosteroids in an unstable daily dose
* Patients with a recent history of myocardial infarction
* A known hypersensitivity to anticholinergic drugs

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo Controlled, Multicenter, Phase 3 Study of Rosuvastatin (CRESTOR®) 20 mg in the Prevention of Cardiovascular Events Among Subjects With Low Levels of Low Density Lipoprotein(LDL) Cholesterol & Elevated Levels of C-Reactive Protein
Brief Summary: The purpose of this study is to determine the safety and effectiveness of long-term therapy with rosuvastatin compared with a placebo, and to evaluate whether treatment with rosuvastatin might be effective in reducing the risk of major cardiovascular events.


Options:
A: Inclusion Criteria:

* Men 50 years or older, women 60 years or older
* Low to normal levels of low density lipoprotein (LDL) cholesterol (\< 130mg/dL)
* Elevated levels of C-Reactive Protein (CRP) \> 2.0 mg/L

Exclusion Criteria:

* History of cardiovascular or cerebrovascular events
* Active liver disease
* Diabetes mellitus
* Uncontrolled hypertension or hypothyroidism
* History of certain malignancies
* Chronic inflammatory conditions
* History of alcohol or drug abuse
B: Inclusion Criteria:

* TC:220～270mg/dl
* Male: 40-70 years old/ female: postmenopausal-70 years old
* \<40kg in weight

Exclusion Criteria:

* FH
* History of CHD(angina, MI, post-PTCA/CABG, etc.)
* History of CVA(stroke, TIA, etc.)
* Underlying malignant tumor
C: Inclusion Criteria:

1. edss\<5
2. \>=1 attack in last year

Exclusion Criteria:

1. \>2 attacks in study
2. drug complication
D: Inclusion Criteria:

* Maximum IMT \>1.2 mm and 3.5 mm at any location in the carotid ultrasound studies conducted at both Visit 2 (Week -4) and Visit 3 (Week -2)
* Subjects with age and no other risk factor: Fasting LDL-C at Visit 1 (Week -6) is \>120 mg/dL (3.1mmol/L) and \<190 mg/dL (4.9 mmol/L)
* Subjects with 2 or more risk factors and a 10-year coronary heart disease (CHD) risk \< 10%: Fasting LDL-C at Visit 1 (Week -6) is \>120 mg/dL (3.1 mmol/L) and \<160 mg/dL (4.1 mmol/L)

Exclusion Criteria:

* Use of pharmacologic lipid-lowering medications (eg, HMG-CoA reductase inhibitors, fibrate derivatives, bile acid binding resins, niacin or its analogues at doses \>400 mg) within 12 months prior to Visit 1 (Week -6).
* Clinical evidence of coronary artery disease or any other atherosclerotic disease such as angina, MI, TIA, symptomatic carotid artery disease, CVA, CABG, PTCA, peripheral arterial disease, AAA.

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Urinary Incontinence After Radical Prostatectomy. - Effect of Pelvic Floor Muscle Training. A Randomised Controlled Trial
Brief Summary: The aim of this study is to evaluate the effect of pelvic floor muscle training in the treatment of urinary incontinence after radical prostatectomy.


Options:
A: Inclusion Criteria:

* Scheduled to undergo nerve sparing radical prostatectomy
* Continent before surgery
* A minimum score on the IIEF-questionnaire of 18
* Sexually active

Exclusion Criteria:

* Treatment with nitrates
* Treatment with α-blockers
* Serious cardiovascular disease
* Severely reduced liver function,
* Retinitis pigmentosa,
* Non-arteritic ischemic optic neuropathy (NAION)
* Previous vascular infarction of the eye
B: Inclusion Criteria:

* Cancer prostata operated (radical prostatectomy)
* Incontinence after separation of catheter
* Understands Norwegian language

Exclusion Criteria:

* Drug/alcohol abuse
C: Inclusion Criteria:

* Patients with localized og locally advanced prostate cancer treated with curative intended radiotherapy at Department of Oncology Odense University Hospital in the period of inclusion

Exclusion Criteria:

* Patients younger than 18
* Patients who cannot understand/read or speak danish
D: DISEASE CHARACTERISTICS:

* Men who have undergone a radical prostatectomy for prostate cancer or men who have undergone a transurethral resection of the prostate for benign prostatic hypertrophy
* Urinary incontinence at six weeks after prostate surgery

  * Incontinence is defined as a response on the screening questionnaire indicating a loss of urine including how often and how much

PATIENT CHARACTERISTICS:

* Able to comply with intervention
* Able to complete study questionnaires

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* No referral for formal therapy (teaching of pelvic floor muscle training) due to prostate surgery
* No concurrent or planned radiotherapy during the first 3 months after surgery
* No palliative endoscopic resection of prostate due to outflow obstruction for advanced prostate cancer

Answer: B